Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07790913 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma

StatusNot Yet Recruiting
PhasePhase 2
Started2026-10
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from St. Jude Children's Research Hospital

Amendment history

2026-09-24
Primary endpoint(s) modified1 to 2 entries
WasDetermine feasibility of obesity treatment with phentermine/extended-release topiramate (PHEN/TOP) compared to lifestyle alone (SOC) in patients 12-<25 years with ALL or lymphoma and obesity in maintenance therapy or up to 2 years off therapy.
NowDetermine feasibility of obesity treatment with phentermine/topiramate ER plus health behavior and lifestyle counseling (PHEN/TOP) versus lifestyle counseling alone (SOC) in adolescents and young adults with ALL or lymphoma., Determine the feasibility of completing obesity treatment with phentermine/topiramate ER plus health behavior and lifestyle counseling (PHEN/TOP) versus lifestyle counseling alone as standard care in adolescents and young adults with ALL or lymphoma.
Enrollment increased: 45 → 100 participants
This study is evaluating whether a weight-loss medication (PHEN/TOP) combined with healthy lifestyle counseling is safe, well tolerated, and can help reduce obesity in adolescents and young adults who are in remission from ALL, Hodgkin lymphoma, or non-Hodgkin lymphoma. Participants are randomly assigned to receive either PHEN/TOP plus counseling or counseling alone for 24 weeks and are followed for up to 52 weeks.
Trial Details
NCT Number NCT07790913
Lead Sponsor St. Jude Children's Research Hospital
Conditions Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
Enrollment 100 participants
Start Date 2026-10
Primary Completion 2030-08 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-23